Activation of peroxisome proliferator-activated receptors α and γ1 inhibits human smooth muscle cell proliferation

  • Peter Zahradka
  • Natalia Yurkova
  • Brenda Litchie
  • Michael C. Moon
  • Dario F. Del Rizzo
  • Carla G. Taylor
Part of the Molecular and Cellular Biochemistry: An International Journal for Chemical Biology in Health and Disease book series (DMCB, volume 41)

Abstract

Atherosclerotic lesions occur as a result of excess lipid deposition within the vascular tissues. The peroxisome proliferatoractivated receptors (PPARs) present in adipose and hepatic tissues have been shown to promote fatty acid oxidation and lipid storage. An immunohistochemical assessment of PPARα and PPARγ revealed both proteins were also present in the medial and intimal layers of human arteries, predominately in regions containing smooth muscle cells. In agreement with this observation, smooth muscle cells isolated from these vessels were found by RT-PCR to express both PPARα and PPARγl. The functionality of these receptors was tested with selective PPAR agonists. Mitogenic stimulation of smooth muscle cell proliferation was blocked by 15d-PGJ2, a PPARγ agonist, as well as by WY14643, a PPARα agonist. These data indicate PPAR activation by selective agonists could influence lesion progression directly, as well as indirectly through reductions in serum lipoprotein and triglyceride levels. (Mol Cell Biochem 246: 105–110, 2003)

Keywords

peroxisome proliferator-activated receptor human smooth muscle DNA synthesis WY 14643 PGJ2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr Opin Lipidol 12: 245–254, 2001PubMedCrossRefGoogle Scholar
  2. 2.
    Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32:187–204, 2000PubMedCrossRefGoogle Scholar
  3. 3.
    Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: A mechanism to improve energy balance and insulin resistance. Br J Nutr 83(suppl 1): S59–S66, 2000PubMedCrossRefGoogle Scholar
  4. 4.
    Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93–109, 1996PubMedCrossRefGoogle Scholar
  5. 5.
    Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790–793. 1998PubMedCrossRefGoogle Scholar
  6. 6.
    Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370–374, 1998PubMedCrossRefGoogle Scholar
  7. 7.
    Chinetti G, Griglio S. Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferatoractivated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573–25580, 1998PubMedCrossRefGoogle Scholar
  8. 8.
    Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach VV, Libby P, Plutzky J: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103: 213–219, 2001PubMedCrossRefGoogle Scholar
  9. 9.
    Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546–551, 1999PubMedCrossRefGoogle Scholar
  10. 10.
    Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125–3131, 1999PubMedCrossRefGoogle Scholar
  11. 11.
    Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors with functions in the vascular wall. Z Kardiol 90(suppl 3): 125–132, 2001PubMedCrossRefGoogle Scholar
  12. 12.
    Miwa Y, Sasaguri T, Inoue H, Taba Y, Ishida A, Abumiya T: 15-Deoxydelta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 58: 837–844, 2000PubMedGoogle Scholar
  13. 13.
    Gouni-Berthold I, Berthold HK, Weber AA, Seul C, Vetter H, Sachinidis A: Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp Clin Endocrinol Diabetes 109: 203–209, 2001PubMedCrossRefGoogle Scholar
  14. 14.
    Del Rizzo DF, Yurkova N, Moon MC, Litchie B, Zahradka P: Platelet-derived growth factor-induced expression of c-fos in human vascular smooth muscle cells: Implications for long-term graft patency. Ann Thorac Surg 74: 90–95, 2002PubMedCrossRefGoogle Scholar
  15. 15.
    Zahradka P, Elliot T, Hovland K, Larson DE, Saward L: Repression of histone gene transcription in quiescent 3T6 fibroblasts. Eur J Biochem 217: 683–690, 1993PubMedCrossRefGoogle Scholar
  16. 16.
    Zahradka P, Harris KD, Triggs-Raine B, Lamontagne G, Leblanc N: PCR-based analysis of voltage-gated K+ channels in vascular smooth muscle. Mol Cell Biochem 145: 39–44, 1995PubMedCrossRefGoogle Scholar
  17. 17.
    Marx N, Schonbeck If, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097–1103, 1998PubMedCrossRefGoogle Scholar
  18. 18.
    Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA: Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone. Am J Hypertens 13: 74–82, 2000PubMedCrossRefGoogle Scholar
  19. 19.
    Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311–1318, 2000PubMedCrossRefGoogle Scholar
  20. 20.
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman Q Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418, 1999PubMedCrossRefGoogle Scholar
  21. 21.
    Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523–531, 2000PubMedCrossRefGoogle Scholar
  22. 22.
    Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K: Troglitazone reduces neointimal tissue prolifera-tion after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 36: 1529–1535, 2000PubMedCrossRefGoogle Scholar
  23. 23.
    Elangbam CS, Tyler RD, Lightfoot RM: Peroxisome proliferator-activated receptors in atherosclerosis and inflammation – an update. Toxicol Pathol 29: 224–231, 2001PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang X, Wang JM, Gong WH, Mukaida N, Young HA: Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J Immunol 166: 7104–7111, 2001PubMedGoogle Scholar
  25. 25.
    Chiba Y, Ogita T, Ando K, Fujita T: PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun 286: 541–546, 2001PubMedCrossRefGoogle Scholar
  26. 26.
    Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61: 6213–6218, 2001PubMedGoogle Scholar
  27. 27.
    Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA: Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49: 346–355, 2000PubMedCrossRefGoogle Scholar
  28. 28.
    Betz E, Quack G: Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. Vasa 19: 157–160, 1990PubMedGoogle Scholar
  29. 29.
    Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clayey V, Staels B: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53–58, 2001PubMedCrossRefGoogle Scholar
  30. 30.
    Jones DC, Ding X, Daynes RA: Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277: 6838–6845, 2002PubMedCrossRefGoogle Scholar
  31. 31.
    Diep QN, Touyz RM, Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 36: 851–855, 2000PubMedCrossRefGoogle Scholar
  32. 32.
    Ma X, Stoffregen DA, Wheelock GD, Rininger JA, Babish JG: Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats. Mol Pharmacol 51: 69–78, 1997PubMedGoogle Scholar
  33. 33.
    Zahradka P, Werner JP, Buhay S, Litchie B, Thomas S: NF-KB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34: 1609–1621, 2002PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Peter Zahradka
    • 1
    • 4
  • Natalia Yurkova
    • 1
  • Brenda Litchie
    • 1
  • Michael C. Moon
    • 1
    • 3
    • 4
  • Dario F. Del Rizzo
    • 3
  • Carla G. Taylor
    • 2
  1. 1.Institute of Cardiovascular SciencesSt. Boniface General Hospital Research CentreWinnipegCanada
  2. 2.Department of Human Nutritional SciencesUniversity of ManitobaWinnipegCanada
  3. 3.Department of SurgeryUniversity of ManitobaWinnipegCanada
  4. 4.Department of PhysiologyUniversity of ManitobaWinnipegCanada

Personalised recommendations